ILLUMINATE-A, a phase 3 study of lumasiran, an investigational RNAi therapeutic, in children and adults with primary hyperoxaluria type 1 (PH1)

被引：0

作者：

Garrelfs, Sander ^{[1
]}

Frishberg, Yaacov ^{[2
]}

Hulton, Sally ^{[3
]}

Koren, Michael ^{[4
]}

O'Riordan, William ^{[5
]}

Cochat, Pierre ^{[6
,7
,8
]}

Deschenes, Georges ^{[9
]}

Shasha-Lavsky, Hadas ^{[10
]}

Saland, Jeffrey ^{[11
]}

van't Hoff, William ^{[12
]}

Fuster, Daniel G. ^{[13
]}

Magen, Daniella ^{[14
]}

Moochhala, Shabbir ^{[15
]}

Schalk, Gesa ^{[16
]}

Simkova, Eva ^{[17
]}

Groothoff, Jaap ^{[1
]}

Sas, David ^{[18
]}

Meliambro, Kristin ^{[11
]}

Lu, Jiandong ^{[19
]}

Garg, Pushkal ^{[19
]}

Gansner, John ^{[19
]}

McGregor, Tracy ^{[19
]}

Lieske, John ^{[18
]}

机构：

[1] Amsterdam UMC, Dept Pediat Nephrol, Amsterdam, Netherlands

[2] Shaare Zedek Med Ctr, Div Pediat Nephrol, Jerusalem, Israel

[3] Birmingham Childrens Hosp, Dept Nephrol, Birmingham, W Midlands, England

[4] Jacksonville Ctr Clin Res, Jacksonville, FL USA

[5] EStudySite, San Diego, CA USA

[6] Hosp Civils Lyon, Lyon, France

[7] Univ Lyon, Ctr Rare Renal Dis, Lyon, France

[8] INSERM, Pediat Clin Invest Ctr, Lyon, France

[9] Hosp Robert Debre, Dept Pediat Nephrol, Paris, France

[10] Galilee Med Ctr, Nahariyya, Israel

[11] Icahn Sch Med, New York, NY USA

[12] Great Ormond St Hosp Sick Children, Dept Pediat Nephrol, London, England

[13] Univ Bern, Div Nephrol & Hypertens, Inselspital, Univ Hosp Bern, Bern, Switzerland

[14] Rambam Hlth Care Campus, Dept Pediat Nephrol, Haifa, Israel

[15] Royal Free Hosp, London, England

[16] Univ Bonn, Bonn, Germany

[17] Al Jalila Childrens Hosp, Dubai, U Arab Emirates

[18] Mayo Clin, Rochester, MN USA

[19] Alnylam Pharmaceut, Cambridge, MA USA

来源：

SWISS MEDICAL WEEKLY | 2020年

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OC 15

引用

页码：8S / 8S

页数：1

共 50 条

[1] ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Garrelfs, Sander
Frishberg, Yaacov
Hulton, Sally
Koren, Michael
O'Riordan, William
Cochat, Pierre
Deschenes, Georges
Shasha-Laysky, Hadas
Saland, Jeffrey
Van't Hoff, William
Fuster, Daniel Guido
Magen, Daniella
Moochhala, Shabbir
Schalk, Gesa
Simkova, Eva
Groothoff, Jaap
Sas, David
Meliambro, Kristin
Lu, Jiandong
Garg, Pushkal
Gansner, John
McGregor, Tracy
Lieske, John
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 2183 - 2183
[2] SAFETY AND EFFICACY STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC, IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Frishberg, Yaacov
Deschenes, Georges
Cochat, Pierre
Magen, Daniella
Groothoff, Jaap
Hulton, Sally A.
Harambat, Jerome
Hoff, William Vant
Hoppe, Bernd
Lieske, John C.
McGregor, Tracy L.
Haslett, Patrick
Talamudupula, Sandeep
Erbe, David V.
Milliner, Dawn S.
JOURNAL OF UROLOGY, 2019, 201 (04) : E174 - E174
[3] Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Garrelfs, Sander F.
Frishberg, Yaacov
Hulton, Sally A.
Koren, Michael J.
O'Riordan, William D.
Cochat, Pierre
Deschenes, Georges
Shasha-Lavsky, Hadas
Saland, Jeffrey M.
van't Hoff, William G.
Fuster, Daniel G.
Magen, Daniella
Moochhala, Shabbir H.
Schalk, Gesa
Simkova, Eva
Groothoff, Jaap W.
Sas, David J.
Meliambro, Kristin A.
Lu, Jiandong
Sweetser, Marianne T.
Garg, Pushkal P.
Vaishnaw, Akshay K.
Gansner, John M.
McGregor, Tracy L.
Lieske, John C.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13) : 1216 - 1226
[4] Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Garrelfs, Sander F.
Gansner, John M.
Lieske, John C.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (20) : E69 - E69
[5] A Phase 1/2 Trial of ALN-GO1, an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1 (PH1)
Hulton, S-A.
Frishberg, Y.
Milliner, D.
Hoppe, B.
Lorch, U.
Olgesbee, D.
Lieske, J.
Haslett, P.
PEDIATRIC NEPHROLOGY, 2016, 31 (10) : 1763 - 1763
[6] Re: Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
不详
JOURNAL OF UROLOGY, 2021, 206 (05) : 1322 - 1322
[7] Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children
Sas, David J.
Magen, Daniella
Hayes, Wesley
Shasha-Lavsky, Hadas
Michael, Mini
Schulte, Indra
Sellier-Leclerc, Anne-Laure
Lu, Jiandong
Seddighzadeh, Ali
Habtemariam, Bahru
McGregor, Tracy L.
Fujita, Kenji P.
Frishberg, Yaacov
GENETICS IN MEDICINE, 2022, 24 (03) : 654 - 662
[8] PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR PRIMARY HYPEROXALURIA TYPE
Habtemariam, B.
Attarwala, H.
Cao, K.
Clausen, V.
Goel, V.
Melch, M.
McGregor, T. L.
Robbie, G. J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S37 - S37
[9] A PHASE 1/2 TRIAL OF LUMASIRAN (ALN-GO1), AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR PRIMARY HYPEROXALURIA TYPE 1
Frishberg, Yaacov
Cochat, Pierre
Vant Hoff, William
Hulton, Sally
Mcgregor, Tracy L.
Haslett, Patrick
Erbe, David V.
Deschenes, Georges
PEDIATRIC NEPHROLOGY, 2018, 33 (10) : 1814 - 1815
[10] RESPONSE TO LUMASIRAN IN PRIMARY HYPEROXALURIA TYPE 1 (PH1): FIRST CLINICAL EXPERIENCES
Saffe, Sina
Kemper, Markus J.
Hansen, Matthias
Kanzelmeyer, Nele
Buescher, Anja
Oh, Jun
Doerry, Katja
PEDIATRIC NEPHROLOGY, 2022, 37 (11) : 2854 - 2854

← 1 2 3 4 5 →